Murata HCR Redefines Automotive Timing Devices With the Total Frequency Tolerance of ±40PPM Under -40°C to +125°C Operation
14.11.2024 03:00:00 CET | Business Wire | Press release
Murata Manufacturing Co., Ltd. (TOKYO:6981) (ISIN:JP3914400001) unveils a cutting-edge electronic timing device featuring exceptional accuracy ±40ppm and reliability even in wide-temperature -40°C to +125°C conditions. By addressing the limitations of current timing components in automotive electronic systems, it enhances the design and deployment of next-generation In-Vehicle Networks (IVN), wireless communication, and Advanced Driver Assistance Systems (ADAS) functions.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241113670074/en/
Murata Manufacturing Co., Ltd.: The new Timing Devices, XRCGE_M_F series (Photo: Business Wire)
As the automotive industry continues to pursue greater integration and electronic downsizing to address the expanding number of critical electronic systems, the performance requirements for components are growing. In order to achieve tighter packaging without compromising accuracy, it is now necessary for critical components like timing devices to have higher temperature limits. There is also a growing demand to incorporate features like Bluetooth® Low Energy (BLE) and ethernet in vehicles, which demands more accurate timing than what is typically offered by automotive crystal units.
Murata’s high accuracy and high temp automotive crystal (HCR), or XRCGE_M_F series, redefines timing component performance and reliability. It sets a new global standard as the first of its kind to achieve a total frequency tolerance of ±40 ppm throughout an operating temperature range of -40°C to +125°C. This combination allows automotive engineers to achieve the stable and highly accurate timing without the need for system calibration or temperature compensation measures, reducing development efforts and costs.
Murata has a long-standing history of being at the forefront of automotive timing solutions, starting with the introduction of its ceramic resonators in 1997 and followed by its crystal units in 2015 – HCR is the next step. Through the optimization of artificial crystal growth, assembly, and inspection, Murata’s groundbreaking resin-sealed package technology, along with the optimization of crystal design, allows HCR to achieve high-temperature operation and high accuracy. This combination is perfectly suited to support the latest vehicle communication and safety functions such as CAN and ethernet IVNs, ADAS components like cameras, LIDAR, and RADAR, as well as wireless communication technologies such as RF, NFC, BLE, ZigbeeTM, and UWB.
“HCR is a true step forward that perfectly aligns with the latest automotive demands,” said Munenori Hikita, Director of Functional Devices Division at Murata. “With our ‘world’s first’ solution, engineers will be able to deploy downsized designs and high performance communication circuits without compromise.”
The HCR lineup is underpinned by Murata’s stable and reliable multi-source supply chain, ensuring automotive users have no concerns over supply, while its high temperature operating window and strong resistance to solder cracks guarantee long-term reliability. The components have already entered mass production and samples are available upon request. To learn more or to request samples, please contact your local Murata’s representative or visit here.
Please contact us for details: contact form
View source version on businesswire.com: https://www.businesswire.com/news/home/20241113670074/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Wyss Geneva Steps Into Its Next Chapter11.6.2026 13:33:00 CEST | Press release
Dr. Tracy Laabs named Director; Prof. Dr. Erwin Böttinger honored for his transformative leadership The Wyss Center for Bio and Neuroengineering in Geneva is pleased to announce the appointment of Dr. Tracy Laabs as Director, effective July 1st 2026. Dr. Laabs succeeds Prof. Dr. Erwin Böttinger, who leaves behind a fundamentally transformed organization: one that no longer just pursues breakthrough science but systematically turns it into ventures that reach patients. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260611328520/en/ Dr. Tracy Laabs, incoming Director, Wyss Center Geneva Since joining the Wyss Center as Director in April 2023, Prof. Böttinger brought a bold vision: to evolve the Center from a portfolio of promising projects into a disciplined engine for venture creation. Under his leadership, the Center spun off six companies in two years (including ABILITY Neurotech SA and Clee Medical SA in 2025) while simult
BeOne Showcases Landmark Phase 3 Data in CLL Patients Aged 80+ at EHA 2026, Reinforcing BRUKINSA Benefit11.6.2026 13:24:00 CEST | Press release
Nearly two-thirds of patients aged 80+ treated with BRUKINSA remained progression-free at six years, despite advanced age and high-risk featuresNew European patient research reveals safety, disease severity, and effectiveness are the top drivers for first-line CLL treatment decisions – not time on therapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced the presentation of a large Phase 3 dataset in patients with chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) aged 80 and older, showing sustained benefit with BRUKINSA after nearly 6.5 years of follow-up, reinforcing its role as the foundational BTK inhibitor. BRUKINSA is the only BTK inhibitor to demonstrate superior efficacy vs. ibrutinib in a Phase 3 trial.1 These data, one of the largest datasets of older patients with treatment-naive CLL, will be presented at the 2026 European Hematology Association (EHA) Congress in Stockholm, Sweden. Amit Agarwal, M.D.,
Takeda’s Zasocitinib Significantly Outperforms Deucravacitinib in Head-to-Head Phase 3 Psoriasis Study, Promising to Redefine Oral Treatment Expectations11.6.2026 13:00:00 CEST | Press release
Once-daily oral zasocitinib demonstrated statistical superiority over deucravacitinib for all primary and key secondary endpoints in plaque psoriasis study More than 35% of zasocitinib-treated patients achieved complete skin clearance (PASI 100) at week 16 – more than 2.5 times the response rate for deucravacitinib Safety profile was consistent with previous studies with no new safety signals identified Takeda (TSE:4502/NYSE:TAK) announced positive topline results for the Phase 3, randomized, multicenter, double-blind study comparing zasocitinib (TAK-279), an investigational, next-generation, highly selective and potent oral tyrosine kinase 2 (TYK2) inhibitor, to deucravacitinib in adults with moderate-to-severe plaque psoriasis (PsO). In the LATITUDE Atlas (TAK-279-PsO-3004) head-to-head study, zasocitinib demonstrated statistical superiority over deucravacitinib for the primary endpoint, Psoriasis Area and Severity Index (PASI) 100 response rate at week 16. The study also demonstrate
Clearlake Expands Liquid Credit Platform With Acquisition of LCM Asset Management’s CLO Contracts11.6.2026 13:00:00 CEST | Press release
Transaction adds 31 CLOs and more than $5 billion of AUM, strengthening Clearlake Credit’s position in liquid credit Clearlake Capital Group, L.P. (“Clearlake” or the “Firm”), a global investment firm managing integrated platforms spanning private equity, liquid and private credit, and other related strategies, today announced that its credit platform, Clearlake Credit, will assume management of CLOs managed by LCM Asset Management, LLC. The transaction adds 31 CLOs representing more than $5 billion of assets under management and increases assets managed by Clearlake Credit to approximately $39 billion across liquid credit, private credit, and other customized credit solutions. The acquisition further broadens the Firm’s capabilities, deepens its relationships with institutional investors, and reinforces its client-centric approach and commitment to seeking attractive risk-adjusted returns across market cycles. Milbank LLP and Dechert LLP represented Clearlake Credit in the transaction
L&T Technology Services, Databricks Partner to Deliver Industrial AI at Scale for Asset-Intensive Industries11.6.2026 12:30:00 CEST | Press release
Partnership brings together LTTS’ expertise in its Sustainability segment and the Databricks platform to accelerate Engineering Intelligence across industrial operations. L&T Technology Services (BSE: 540115, NSE: LTTS), a global leader in AI, Digital & ER&D Consulting Services, today announced a strategic go-to-market partnership with Databricks, the leading Data and AI company, to co-develop and deliver Industrial AI solutions that advance Engineering Intelligence (EI) for asset-intensive enterprises. Anchored in LTTS' Sustainability segment, spanning Process Engineering, Discrete Manufacturing and Industrial Products, the partnership will support Energy, Petrochemicals and Industrials clients globally. As industrial organizations seek to unlock greater value from decades of operational and engineering data, the alliance will combine LTTS’ deep domain capabilities with the Databricks platform to transform complex plant data into Engineering Intelligence - enabling improved asset reli
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom